When does Concerta’s patent or exclusivity end?
Concerta is a brand of methylphenidate extended-release tablets. A “drugpatent watch” for Concerta usually tracks the expiration of key patents (and sometimes market exclusivity tied to FDA approvals), because those dates are what determine when generic versions can enter.
To pinpoint the exact expiration dates, the watch typically needs at least one of these:
- The specific Concerta product strength and formulation (because patents can be product- and route-specific).
- The relevant legal entity listed for the branded product/ANDA (different registrants can have different patent estates).
- The exact regulator market (US, EU, UK, Canada, etc.), since watch dates differ by jurisdiction.
What exactly does a “drug patent watch” monitor for Concerta?
A Concerta patent watch generally focuses on several event types:
- Patent expiration dates and any listed patent term adjustments.
- Patent litigation and settlements that can trigger “entry” timing for generics.
- FDA-related milestones (for the US): ANDA submissions, approvals, and any forfeitures or stay/trigger events.
- Exclusivity periods that can delay generic launch even after patents expire.
Is generic Concerta available now, and what determines launch timing?
Generic methylphenidate ER products are often available in some strengths/markets, but launch timing depends on whether remaining patents (or exclusivity) still block approval or marketing in that jurisdiction.
For a Concerta-specific watch, the critical question is whether the generic manufacturer is approved to sell:
- The same dosage form and release characteristics, and
- Under the same approved formulation pathway, while
- Avoiding infringement of any still-active Orange Book-listed patents (US) or equivalent national patent listings elsewhere.
How to set up a Concerta patent watch that won’t miss key patents
For a search-intent-safe watch, you’d usually configure it to include:
- Brand name variants (Concerta) and active ingredient (methylphenidate ER).
- Company assignee/holder(s) linked to the Concerta patent family.
- Jurisdictions you care about (often US first).
- Claim coverage terms for “extended-release methylphenidate” products, not only “Concerta” by name, since patent families can cover the underlying technology rather than the trade name.
What I need from you to give exact Concerta patent-watch dates
Your prompt says “Drugpatent watch concerta” but doesn’t specify the jurisdiction or which “watch” you mean. If you answer these two questions, I can produce the specific expiration/next-event timeline you’re looking for:
1) Which market: US, EU, UK, or another country?
2) Do you want the watch for the exact brand Concerta only, or also for generic methylphenidate ER competitors?
Sources
No sources were provided in your request, and I don’t have access to external patent databases from this chat. If you share links/screenshots from the drugpatent watch page you’re using (or tell me the jurisdiction and listing you want), I can extract and organize the exact patent/exclusivity dates and key litigation events from that material.